Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PC-SPES studies

This article was originally published in The Tan Sheet

Executive Summary

NCCAM-funded PC-SPEStrials, on hold since BotanicLab recalled the supplement in February, will remain in limbo until at least July, NIH center says. NCCAM decision-makers currently are meeting with PC-SPES study "stakeholders," patients, researchers to determine course of action. Trial's investigators hope additional sources of PC-SPES will become available. Of the four trials, three were in vitro studies; research involving humans had not yet begun (1"The Tan Sheet" June 3, 2002, p. 5)...

You may also be interested in...



PC-SPES study decision

NCCAM anticipates releasing a decision on future of PC-SPES research "toward the end of August," NIH center states June 14. Four studies were placed on hold after February recall of the dietary supplement, coupled with sole manufacturer BotanicLab's subsequent shutdown (1"The Tan Sheet" June 3, 2002, In Brief)...

Future NCCAM Botanical Study Standards To Reflect PC-SPES Lessons

The NIH National Center for Complementary & Alternative Medicine is expected to impose stricter standards on products used in research it funds in light of the PC-SPES contamination problems

Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions

Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel